Investigative Summary: Findings of Misconduct by a then Senior Official with the Drug Enforcement Administration for Misuse of Official Position Related to Giving Preferential Treatment to a Pharmaceutical Company, and Related Misconduct
- NARA ID
- investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Source
- oig-doj
- Collection
- DOJ OIG — Drug Enforcement Administration
- Agency
- U.S. DOJ Office of the Inspector General
- Classification
- Investigation
- Released
- 2021-12-02
- Slug
- doj-oig-investigative-summary-findings-misconduct-then-senior-official-drug-enforcement
- Indexed
- 2026-04-27 05:02:45
More from DOJ OIG — Drug Enforcement Administration
- Audit of the Drug Enforcement Administration's Regional Linguist Services Contract Awarded to Conduit Language Specialists, Inc.
- Audit of the Drug Enforcement Administration's Confidential Source Policies and Oversight of Higher-Risk Confidential Sources
- Audit of the Drug Enforcement Administration’s Community-Based Efforts to Combat the Opioid Crisis
- Review of the Drug Enforcement Administration’s Accounting of Drug Control Funding Fiscal Year 2025
- Notification of Concerns Identified in the Drug Enforcement Administration’s Transportation Interdiction Activities
- Audit of the Drug Enforcement Administration's Personnel Resource Management and Casework
Browse all 58 documents in DOJ OIG — Drug Enforcement Administration →
About the DOJ OIG — Drug Enforcement Administration collection
U.S. DOJ Office of the Inspector General reports (audits, investigations, evaluations, and reviews) concerning Drug Enforcement Administration.